Clinical Trial Update: Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating erlotinib (Tarceva) with first-line platinum-containing chemotherapy for advanced head and neck squamous cell carcinoma was terminate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Henry Ford Health System | Conditions: Head and Neck Cancer, Carcinoma, Squamous Cell | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2025-03-18